Skip to Main Content

Pfizer plans to close its neuroscience discovery and early development programs, the latest large drug maker to turn its corporate back on developing drugs for central nervous system disorders. As a result, about 300 jobs are being eliminated from three different Pfizer locations — Cambridge and Andover, Mass., and Groton, Conn.

The programs were primarily focused on Alzheimer’s and Parkinson’s disease, according to a Pfizer spokesman. As of Oct. 31, a Pfizer web page that is no longer visible listed nine neuroscience projects under way — six that were in Phase 1, two more in Phase 2, and another in Phase 3.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED